Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: Results of the prospective EORTC-GIMEMA AML-13 study

Haematologica

Volumn 92, Issue 3, 2007, Pages 389-396

  Thomas, Xavier ^a   Suciu, Stefan ^b   Rio, Bernard ^c   Leone, Giuseppe ^d   Broccia, Giorgio ^e   Fillet, George ^f   Jehn, Ulrich ^g   Feremans, Walter ^h   Meloni, Giovanna ⁱ   Vignetti, Marco ⁱ   De Witte, Theo ^j   Amadori, Sergio ^k  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b EORTC DATA CENTER   (Belgium)

^c HÔTEL DIEU   (France)

^d CATHOLIC UNIVERSITY   (Italy)

^e Ospedale Oncologico A Businco   (Italy)

^f CHU SART TILMAN   (Belgium)

^g UNIVERSITY OF MUNICH   (Germany)

^h ERASME HOSPITAL   (Belgium)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

Acute myeloid leukemia; Autologous stem cell transplantation; Elderly

Indexed keywords

AMSACRINE; CARMUSTINE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; BAVC PROTOCOL; GRANULOCYTE COLONY STIMULATING FACTOR; ICE PROTOCOL 4; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRANULOCYTE; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEM CELL; THROMBOCYTE; TREATMENT REFUSAL; WORLD HEALTH ORGANIZATION; AUTOTRANSPLANTATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDARUBICIN; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 34247564702     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10552     Document Type: Article

References (34)

1. Harousseau JL. Acute myeloid leukemia in the elderly. Blood Rev 1998;12:145-53.
2. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17:3569-76.
3. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9.
4. Baudard M, Marie JP, Cadiou M, Viguie F, Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994;86:82-91.
5. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, et al. Etoposide in acute nonlymphoblastic leukemia. The Australian eukemia Study Group. Blood 1990; 75:27-32.
6. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331: 896-903.
7. Schiller G, Lee M, Miller T, Liu M, Mittal-Henkle A, Paquette R, Sawyers C, et al. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission. Leukemia 1997;11:1533-9.
8. Burnett AK, Goldstone AH, Stevens R, Hann IM, Rees JK, Gray RG, et al. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML10 trial. Lancet 1998; 351:700-8.
9. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997;90:2978-86.
10. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission. Leukemia 1996; 10:1874-82.
11. Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332:217-23.
12. Hartmann O, Le Corroler AG, Blaise D, Michon J, Philip I, Norol F, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126:600-7.
13. Henon PR, Liang H, Beck-Wirth G, Eisenmann JC, Lepers M, Wunder E, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cells transplants. Bone Marrow Transplant 1992;9:285-91.
14. Martin C, Torres A, Leon A, Rubio V, Alvarez MA, Herrera C, et al. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first remission. Role of intensification therapy in outcome. Bone Marrow Transplant 1998;21:375-82.
15. Schwartzberg L, Birch R, Blanco R, Wittlin F, Muscato J, Tauer K, et al. Rapid and sustained hematopoietic reconstitution by peripheral stem cell infusion alone following high dose therapy. Bone Marrow Transplant 1993;11:369-74.
16. To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-84.
17. Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999;13:843-9.
18. Montillo M, Tedeschi A, Pagano L, Venditti A, Ferrara F, Fabris P, et al. Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the GIMEMA Group. Br J Haematol 2000;111:334-7.
19. Gorin NC, Labopin M, Pichard P, Sierra J, Fiere D, Rio B, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Haematol 2000;110:887-93.
20. Ferrara F, Venditti A, Carellajr AM, Cantore N, Buccisano F, Tamburini A, et al. Autologous stem cell transplantation for patients with acute myeloid leukemia aged over 60 yr. Eur J Haematol 2002;69:200-4.
21. Oriol A, Ribera JM, Esteve J, Guardia R, Brunet S, Bueno J, et al. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Haematologica 2004;89:791-800.
22. Ferrara F, D'Arco AM, De Simone M, Mele G, Califano C, Pocali B, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 776-84.
23. Lashkari A, Lowe T, Collison E, Paquette R, Emmanouilides C, Territo M, et al. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or = 60 years with acute myelogenous leukemia. Biol Blood Marrow Transplant 2006;12:466-71.
24. Meloni G, De Fabritis P, Petti MC, Mandelli F. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990;75:2282-5.
25. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. EORTC/GIMEMA Leukemia Group. Blood 2005;106: 27-34.
26. Jehn U, Suciu S, Thomas X, Lefrere F, Muus P, Berneman Z, et al. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 phase III trial. Leukemia 2006;20:1723-30.
27. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620-5.
28. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991;78: 325-9.
29. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982;60:454-62.
30. Mitelman F. An International System for Human Cytogenetic Nomenclature. Mitelman F, editor. S. Karger: Basel. 1995.
31. Kalbfleisch JD and Prentice RL. The Survival Analysis of Failure Time Data. 2nd ed. Wiley-Interscience. New Jersey; USA. 2002.
32. + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997;19:303-10.
33. Mazza P, Palazzo G, Amurri B, Cervellera M, Manna N, Fellini G, et al. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report. Bone Marrow Transplant 1999;23:1273-8.
34. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Canc Control 2001;8:1-25.